v3.26.1

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions	12 Months Ended
	Apr. 24, 2026	Apr. 25, 2025	Apr. 26, 2024
Income Statement [Abstract]
Net sales	$ 3,102	$ 2,715	$ 2,469
Cost of products sold	1,422	1,187	1,032
Gross profit	1,680	1,528	1,436
Operating expenses:
Research and development expense	448	436	437
Selling, general, and administrative expense	1,183	1,080	1,057
Certain litigation charges, net	18	165	0
Other operating expense (income), net	221	(8)	11
Operating loss	(190)	(146)	(69)
Other non-operating expense (income), net	(1)	1	1
Loss before income taxes	(189)	(147)	(70)
Income tax provision	128	52	38
Net loss	(317)	(198)	(107)
Net income attributable to noncontrolling interests	(16)	(15)	(5)
Net loss attributable to the Company	$ (333)	$ (213)	$ (112)
Earnings (loss) per share:
Earnings (loss) per share, basic (usd per share)	$ (1.30)	$ (0.84)	$ (0.44)
Earnings (loss) per share, diluted (usd per share)	$ (1.30)	$ (0.84)	$ (0.44)
Weighted-average shares outstanding
Basic weighted average shares outstanding (shares)	256,600,000	252,800,000	252,800,000
Diluted weighted average shares outstanding (shares)	256,600,000	252,800,000	252,800,000

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

MiniMed Group, Inc. 10-K